US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics’brepocitinib. Exton, PA, October 18, 2024 – Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care predominantly involves corticosteroids, topical therapies, […]
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
With the potential rise of new oral agents, dermatologists are increasingly optimistic about safer, more convenienttreatment options for psoriasis, according to Spherix Global Insights. Exton, PA, October 16, 2024 – Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for convenient, less invasive […]
Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
Incorporation of gene therapies, such as Beqvez (Pfizer),Hemgenix (CSL Behring) and Roctavian (BioMarin), and potential future approvalsof fitusiran (Sanofi) and Mim8/denecimig (Novo Nordisk) will further drive theincreasingly dynamic hemophilia markets. Exton, PA – October 14, 2024 – Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly […]
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in the lupus nephritis treatment landscape, pending approval. EXTON, PA., October 10, 2024 – While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious […]
AbbVie’s Skyrizi leapfrogs Lilly’s Omvoh to take early lead in IL-23 colitis space: survey
AbbVie now faces a more seasoned rival than Eli Lilly. (AbbVie) Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, capturing more than double the market share of its rival two months after launch. But AbbVie now faces another challenger, with Spherix predicting a similarly speedy launch for Johnson & […]
US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights
Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s. EXTON, PA., October 02, 2024 — Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient’s overall functioning. Common symptoms include significant dryness, particularly in the eyes and mouth, along with severe […]
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to Spherix Global Insights. Exton, PA., October 1, 2024 – The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA approval. In June, […]
Docs discuss sluggish switch to Humira biosimilars, name preferred off-patent options
Spherix Global Insights looked at which biosimilar brands stand to benefit as AbbVie loses access. (AbbVie) AbbVie reported global Humira sales of $2.8 billion in the second quarter. That represented a 29% drop on an operational basis but meant Humira remained a major product more than one year on from the launch of the first biosimilar in […]
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
Lupus landscape ‘poised for evolution’ as US doctors eagerly await new entrants
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However, the landscape may be about to change with the […]
